

Meeting with EFPIA

Meeting date and place

Meeting held on 25/01/2021 10:00 in Videoconference

Participating organisation(s) & representative(s)

[Art. 4.1 (b)] -- European Federation of Pharmaceutical Industries and Associations (TRN: 38526121292-88) Participant.

[Art. 4.1 (b)] -- IMC Participant

[Art. 4.1 (b)] -- IMC Participant,

[Art. 4.1 (b)] -- IMC Participant

Main issues discussed

The main purpose of the meeting was for the industry to present their key issues of concern ahead of the EU-Canada Intellectual Property Dialogue.

IMC and EFPIA raised as main concerns the patent term restoration implemented by Canada; the modifications done in the Canadian regulation to integrate the so-called "patent linkage" and the excessive level of liability for lost generic profits.

Directorate or unit

TRADE B/3

Internal participants

[Art. 4.1 (b)]	TRADE B/3	[Art. 4.1 (b)]@ec.europa.eu)	Participant,
[Art. 4.1 (b)]	TRADE B/3	[Art. 4.1 (b)] @ec.europa.eu)	Participant, Notetaker,
[Art. 4.1 (b)]	TRADE D/1	[Art. 4.1 (b)] @ec.europa.eu)	Participant,
[Art. 4.1 (b)]	TRADE D/1/DEL/CANADA/002	[Art. 4.1 (b)]@ec.europa.eu)	Participant,
[Art. 4.1 (b)]	TRADE E/3	[Art. 4.1 (b)] @ec.europa.eu)	Participant,

Author(s) of minutes

[Art. 4.1 (b)]

Validator and validation date

[Art. 4.1 (b)] validated the minutes on 24/02/2021 10:47